Literature DB >> 26756039

Composition, Diversity and Abundance of Gut Microbiome in Prediabetes and Type 2 Diabetes.

Stacey M Lambeth1, Trechelle Carson1, Janae Lowe1, Thiruvarangan Ramaraj2, Jonathan W Leff3, Li Luo1, Callum J Bell2, Vallabh O Shah1.   

Abstract

Association between type 2 diabetes (T2DM) and compositional changes in the gut micro biota is established, however little is known about the dysbiosis in early stages of Prediabetes (preDM). The purpose of this investigation is to elucidate the characteristics of the gut micro biome in preDM and T2DM, compared to Non-Diabetic (nonDM) subjects. Forty nine subjects were recruited for this study, 15 nonDM, 20 preDM and 14 T2DM. Bacterial community composition and diversity were investigated in fecal DNA samples using Illumina sequencing of the V4 region within the 16S rRNA gene. The five most abundant phyla identified were: Bacteroidetes, Firmicutes, Proteobacteria, Verrucomicrobia, and Actinobacteria. Class Chloracido bacteria was increased in preDM compared to T2DM (p = 0.04). An unknown genus from family Pseudonocardiaceae was significantly present in preDM group compared to the others (p = 0.04). Genus Collinsella, and an unknown genus belonging to family Enterobacteriaceae were both found to be significantly increased in T2DM compared to the other groups (Collinsella, and p = 0.03, Enterobacteriaceae genus p = 0.02). PERMANOVA and Mantel tests performed did not reveal a relationship between overall composition and diagnosis group or HbA1C level. This study identified dysbiosis associated with both preDM and T2DM, specifically at the class and genus levels suggesting that earlier treatment in preDM could possibly have an impact on the intestinal micro flora transitioning to T2DM.

Entities:  

Keywords:  Bacterial diversity; Diabetes; Gut microbiome; Prediabetes

Year:  2015        PMID: 26756039      PMCID: PMC4705851          DOI: 10.15436/2376-0949.15.031

Source DB:  PubMed          Journal:  J Diabetes Obes        ISSN: 2376-0494


Introduction

Diabetes & prediabetes

Diabetes mellitus is a group of diseases marked by disordered insulin resulting in elevated blood glucose levels[. This group of diseases affects an estimated 9% of the global population[ and approximately 9.3% or 29.1 million people in the United States[. In 2012, it was estimated to cost the US $245 billion, accounting for both direct and indirect costs[. Type 2 Diabetes Mellitus (T2DM) constitutes at least 90% of diabetes cases in the adult population[. This condition is considered to be a heterogeneous and multi factorial disease, influenced by both environmental and genetic factors[. T2DM continues to be a leading cause of renal failure, non-traumatic limb amputations, and blindness among adults[. It is a major contributor to both cardiovascular disease and stroke, and was reported as the seventh leading cause of death in the US in 2010[. Prediabetes (preDM) is an intermediate state between non-diabetic and diabetic plasma glucose levels[. Specifically, it is defined as: fasting glucose levels 100-125 mg/dl, plasma glucose 140-199 mg/dl on two-hour Oral Glucose Tolerance Test (OGTT), or Glycated Hemoglobin (HbA1C) level between 5.7 and 6.4%[. In 2012 an estimated 37% of US adults, effectively 86 million people, qualify as PreDM[. The preDM state is associated with obesity, hypertension, and hypercholesterolemia and is considered a risk factor for both cardiovascular disease and T2DM[[. Those with HbA1C levels within the preDM range (5.7-6.4%) have an increased relative risk of developing T2DM in 5-years compared to those with normal levels, and the higher the HbA1C, the greater the risk[. Prevention of the transition to T2DM has been proven successful with weight loss, exercise programs, and pharmacologic agents such as Metformin[. Thus far, preDM is considered a multi factorial condition caused by genetic predisposition, increased insulin demand, and decreased pancreatic beta-cell mass[. The patho physiology of the preDM state, and the mechanisms underlying the progression to T2DM are important for the development of further interventions to alleviate the burden of T2DM.

Human microbiome

In recent years, there has been increasing interest in the microbes that inhabit the human body, or the ‘human micro biome’[. This micro biome involves approximately 100 trillion microbial organisms that inhabit and are believed to influence important physiological human processes[. These organisms are thought to interact with their environment through quorum sensing, nutrient production, signaling pathway modulation, and gene transfer[. Interestingly, the human micro biome has been shown to represent a pliable meta genome that varies from individual-to-individual, disease-to disease, and among anatomical locations within each individual[. Characterization of what is considered normal flora, has been undertaken for certain anatomical locations such as the skin, mouth, nasal cavities, vagina, and gastrointestinal tract[. Current micro biome techniques are based on sequencing of the bacterial 16S ribosomal RNA gene, phylogenetically identifying it, and quantifying the number of genes present[. The micro biome is currently being described in terms of richness and diversity, composition, and functionality[. Based on available research, a ‘normal’ or ‘healthy’ gut micro biome is composed of the bacterial phylaFirmicutes and Bacteroidetes (>90%), followed by Actinobacteria and Verrucomicrobia; it contains a very small (0.1%) amount of pathogenic and opportunistic species[. Based on a study of Danish participants[, those who had increased numbers of bacterial genes (richness) exhibited healthier phenotypes and also had the following intestinal micro biome characteristics: presence of methanogenic/acetogenic communities, increased butyrate-producing bacteria, increased ratio of Akkermansia: Ruminococcus torque/gnavus, increased potential for hydrogen production, decreased potential for hydrogen sulfide production, and reduced number of Campylobacter and Shigella genera. Based on available research, the various functions of the intestinal micro biome are preserved despite a wide variety of species composition[. Function is implied by characteristics of the species present, by meta genomic techniques that identify genes involved in functional pathways rather than by phylogeny, and by direct measurement of the byproducts of bacterial metabolism[. Functional pathways being studied include nutrient metabolism and harvest, immuno modulation, and inflammation[. In patients with both local and systemic disease processes, an alteration in the normal micro biota, or dysbiosis, is apparent[. Dysbiosis has been implicated in either the cause orthe effect of localized disease such as dental caries, bacterial vaginosis, and inflammatory bowel disease; and systemic conditions such as obesity or allergies[. The effect of intestinal micro biota on whole-body metabolism and obesity began with studies in mice and quickly expanded to include humans[. Murine studies revealed a relative increase in phylaFirmicutes compared to Bacteroidetesin the intestines of obese mice[, this was confirmed in some human studies[, and not in others[. When examining the function of the gut micro biome, studies have suggested an overall increased capacity for energy harvest from the diet in obese individuals[. The interconnection between gut micro biota and metabolic disease initiated interest into the relationship between gut micro biota and T2DM. One study demonstrated that compositional changes in the intestinal micro biota were associated with T2DM compared to non-diabetic controls[. This study demonstrated a significantly lower abundance of the phylum Firmicutesand class Clostridia, meanwhile a significantly higher abundance of class BetaProteobacteria[. They also found that the ratio of PhylaBacteroidetes: Firmicutes was increased in T2DM and positively correlated with increasing plasma glucose on OGTT[. A study conducted on 345 Chinese individuals[ found no difference in micro biome diversity between T2DM and non-DM patients, but did find differences in composition/ function including increased: butyrate-producing bacteria, opportunistic pathogens, and species with potential for sulfate-reduction and mucin-degradation. They also identified groups of genes that were found to co-exist and were enriched in either T2DM or control subjects; for example, 337 genes belonging to the species Akkermansia muciniphila were enriched in T2DM, whereas 273 genes belonging to Haemophilus parainfluenzae were enriched in control subjects[. There is an increasing body of knowledge on the subject of intestinal dysbiosis in T2DM; however, it is unknown whether these differences occur early in preDM patients, and whether or not they help to mediate the onset of T2DM. A recent study looked at the intestinal micro biota of Chinese individuals who were categorized into three groups based on their Fasting Plasma Glucose (FPG) level[. This study revealed higher levels of class Clostridia and lower level of class Bacteroidia in T2DM compared to preDM and normal groups, genus Streptococcus was most abundant in the normal group and decreased in PreDM and further in the T2DM group, levels of genera Prevotella and Megamonas were higher than in the normal group[. The study presented in this article aims to answer a similar question: what is the composition of the gut micro biome belonging to preDM patients? Does it have similarities to those with T2DM? Does it differ significantly from non-diabetics?

Materials and Methods

Subjects

The University of New Mexico Health Sciences Center Human Research Review Committee Institutional Review Board approved this study and all participants rendered written informed consent and received $25 for their participation. A preDM cohort of 200 participants was initially created in 2012-2014 from established patients attending a primary care clinic of the University of New Mexico Health Sciences Center. For this pilot study a total of 71 willing and available participants were recalled from a Family Practice Clinic in Albuquerque, NM. Information regarding pertinent medical history, demographics, current medications, diet, alcohol and tobacco use was obtained by means of a survey questionnaire administered by a member of the research team. Height, weight, waist circumference, and blood pressure were measured according to standard procedure. Patients who were acutely ill or actively taking antibiotics were excluded. A fasting blood sample was obtained from each subject by venipuncture for the determination of HbA1C, glucose, creatinine, albumin, total protein, uric acid, and lipids. HbA1C values, according to the ADA classification system[, were used to categorize subjects as nonDM (< 5.7 %), preDM (5.7 - 6.4%), or T2DM (> 6.5%). All subjects provided a urine sample for the measurement of Urine Creatinine (UACR) and micro albumin as well as a stool sample for the study of intestinal micro biome. Stool samples were handled as previously described[; samples were frozen at -20°C for up to 24h after voiding and then frozen at -80°C until DNA extraction. Clinical chemistry measurements were performed at the Tricore Reference Laboratories, Albuquerque, NM using clinical diagnostic assays certified by The Clinical Laboratory Improvement Amendments (CLIA) of the Centers for Medicare and Medicaid Services.

DNA Extraction, PCR amplification, and sequencing

DNA was extracted individually from all patients' stool samples using QiaAMP mini stool kit (Qiagen, Valencia, CA, USA). To assess the composition and diversity of the patients' gut bacterial communities, we were able to use only 49 samples with intact and good quantity of DNA to conduct high-throughput sequencing of the V4 region of the 16S rRNA gene[. PCR amplification was performed on this region in triplicate using the 515f/806r primer pair with unique 12 bp barcodes specific to individual samples and combined the resulting product for each sample. PCR product was quantified using the Pico Green dsDNA assay, and the samples' bar-coded amplicons were combined in equimolar concentrations. Sequencing was performed on an Illumina MiSeq instrument to produce 150 bp sequences at the University of Colorado at Boulder.

Gut microbial community composition and diversity

Quality filtering, assignment of sequences to individual samples based on their barcodes, And Operational Taxonomic Units (OTU) clustering was performed using the QIIME (Quantitative Insights into Microbial Ecology) v.1.7.0 pipeline[. The closed reference-based OTU picking protocol was used along with other default parameters[. In this approach sequence reads for each sample were clustered against a reference sequence collection and sequences < 97% similar to any reference sequence were excluded from downstream analyses. This approach implements reference based clustering using the UCLUST[ algorithm and the Green genes[ reference database that covers most of the organisms that are typically present in the human gut micro biome. High percentages (80-90%) of reads were classified using this approach. Because we obtained a variable number of sequences per sample ranging from 14,916 to 36,631 (Supplemental Table 1 for yield per sample after initial processing and closed-reference OTU picking), the sequence data were rarefied to 14,900 sequences per sample to account for this variation. No samples were lost in this study due to rarefaction. This depth of sampling has been shown to be more than sufficient to make assessments of diversity and community composition diversity patterns across varied treatments[.

Statistical analysis

Clinical data was expressed in means plus standard deviations, and differences between the groups were assessed using one-way ANOVA and post-hoc analysis was done by Turkey's honest significance test to find means that are significantly different from each other in normal, preDM and T2DM. For assessment of micro biota, taxa were represented at a particular phylogenetic resolution (phylum, class and genus) that had a relative abundance of at least 0.1% in any of the three groups. The relative abundances were compared across three groups using Kruskal-Wallis rank sum tests[ and if significant, then pair wise comparison; p values were corrected using False Discovery Rate (FDR) to account for multiple comparisons. Principal Component Analysis (PCA) and Per Mutational Multivariate Analysis Of Variance (PERMANOVA) were used to analyze the relationship between overall micro biome composition and diagnosis group, and dissimilarities between composition and HbA1C were assessed using Mantel tests. Three dissimilarity metrics were used: Bray-Curtis, unweighted UniFrac, and weighted UniFrac[. Alpha diversity (within-group diversity) was assessed using Shannon diversity index.

Results

Group characteristics

Demographic and clinical characteristic of the cohort (n = 49) is presented in table 1. Briefly, we recruited more female (n = 32) than male participants in the study cohort and more Caucasian white (n = 28) than Hispanics (n = 15) with three Native Americans and four others (participants didn't identify the race or it was not listed). The age distribution was similar across the three clinical groups with mean age of 55.5 ± 13.7 yrs in nonDM, 56.0 ± 11.5 yrs in preDM, and 62.0 ± 10.0 yrs in T2DM. Body Mass Index (BMI) was not statistically different across the groups (means 29.2 ± 4.8, 29.7 ± 5.8, 32.1 ± 7.2 for nonDM, preDM, and T2DM respectively). Interestingly, LDL levels were significantly lower in the T2DM group than in the nonDM group (77.1 15.8 mg/dl and 93.7± 24.3 mg/dl, respectively, p = 0.04), while the preDM group had significantly higher levels (113.9 ± 30.9 mg/dl) than T2DM and controls (p = 0.0027, p = 0.04, respectively). This is easily explained by the fact that 57% of the T2DM patients, as compared to 13% of control and 25% of preDM, were on a HMG-CoA reductase medication at the time, which is used clinically to decrease serum LDL levels and reduce cardiovascular events. The kidney phenotypes including UACR, uric acid, and creatinine were not different among or between the groups. Though nephropathy marked by albuminuria is a well-known complication of T2DM[, non-difference in the UACR in our population, could be explained by the fact that 36% of T2DM group was taking an ACE inhibitor or angiotensin receptor blocker at the time of interview, which decreases the amount of albumin in the urine[. All patients participating in micro biome analysis were not actively taking antibiotics, nor had they taken any in the one month prior. Eleven participants reported to be on anti-Gastro Esophageal Reflux Disease (GERD) medication and three reported to be taking probiotics.
Table 1

Clinical characteristics of study participants

NonDMPreDMT2DM
N= 49152014
Gender67% F33% M70%F30% M57% F43% M
Age (Yrs)55.5 ± 13.756.0 ± 11.562.0 ± 10.0
BMI (kg/m2)29.2 ± 4.829.7 ± 5.832.1 ± 7.2
Waist (cm)96.0 ± 12.898.7 ± 20.1106.7 ± 19.7
Diabetes Markers
Glucose (mg/dL)92.2 ± 17.894.8 ± 14.5*136.7 ± 32.4*
HbA1c (%)5.4 ± 0.15.9 ± 0.2*7.9 ± 1.7*
Kidney Markers
UACR8.0 ± 5.743.5 ± 109.069.8 ± 131.5
Uric Acid (mg/dL)4.7 ± 1.15.0 ± 1.35.1 ± 1.5
Cr (mg/dL)0.8 ± 0.20.84 ± 0.30.75 ± 0.3
Lipid Panel
Total Cholesterol (mg/dL)177.8 ± 29.0191.6 ± 38.2160.4 ± 27.7*
HDL (mg/dL)53.5 ± 18.452.4 ± 15.7*40.6 ± 13.9*
LDL (mg/dL)93.7 ± 24.3113.9 ± 30.9*77.1 ± 15.8*
Triglyceride (mg/dL)153.4 ± 75.0126.0 ± 61.8234.8 ± 187.2*

Mean ± standard deviation, results of one-way ANOVA and pairwise t- tests.N = NonDM, P = PreDM, D=T2DM. UACR= Urine albumin to creatinine ratio.

Indicates p <0.05

Compositional differences

The output from 49 samples yielded OTU counts ranging from 14,916 to 36,631, with an average of 29,414 for nonDM subjects, 27,438 for preDM, and 28,859 for T2DM (NS). Among these samples there were over 4000 different bacterial species, 440 different genera, 264 families, 90 classes, and 30 phyla. Mean relative abundance and standard deviation are represented for phyla, class, and genera (Supplemental Tables 2a-c). The five most abundant phyla identified were: Bacteroidetes, Firmicutes, Proteobacteria, Verrucomicrobia, and Actinobacteria (Figure 1, Supplemental Table 2a) which is consistent with previous findings[. Relative abundances of Bacteroidetes and Firmicutes were 53.9 and 39.7% respectively in nonDM, 55.0 and 38.2% in preDM, and 53.5 and 34.4% in T2DM (Figure 1). Phylum Synergistetes was significantly increased in T2DM compared to nonDM, however this was nominally significant after FDR correction (Table 2). Three classes out of 90 were identified as significantly different among the groups by Kruskal-Wallis (Table 2). Class Chloracidobacteria was increased in preDM compared to T2DM (p = 0.04). Class Saprospirae was higher in nonDM versus preDM, but this lost significance with FDR correction; similarly, Synergistia was significantly increased in T2DM compared to nonDM before correction. Nine genera out of 440, were identified with some group wise differences (Table 2). An unknown genus from family Pseudonocardiaceae was significantly present in PreDM group compared to the others, whom had none detected (p = 0.04). Genus Collinsella, and an unknown genus belonging to family Enterobacteriaceae were both found to be significantly increased in T2DM compared to the other groups (Collinsella, p = 0.03, Enterobacteriaceae genus p = 0.02). Megasphaera and Candidatus Solibacter were increased in preDM compared to the nonDM group, but were not significant after correction; Lachnospira and an unknown genus belonging to Erysipelotrichaceae were higher in the nonDM group, but also lost significance with correction. Genus Bulleidia was present in T2DM while it was absent in the other groups, which lost significance after correction.
Figure 1

Bacterial composition Using Mean Relative Abundances by Bacterial Phylum. K -indicates kingdom, P - indicates phylum. Bolded names indicate the most abundant phyla.

Table 2

Relative abundance of taxonomies which demonstrated statistical significance after FDR adjustment. P values are for the narrowest taxonomy listed. Results shown are means, group wise and pairwise p values and FDR-adjusted p values.

Bacterial TaxonomyMean Relative AbundanceRaw P value / FDR P value
NPDAllN vs PN vs DP vs D
Synergistetes00.0013%0.0412%*0.0480.230/0.230*0.032/0.0950.120/0.181
Acidobacteria, Chloracidobacteria0.0161%0.0178%0.0091%*0.0380.622/0.6220.067/0.101*0.012/*0.037
Bacteroidetes, Saprospirae0.0300%0.0188%0.0278%*0.048*0.026/0.0780.723/0.7230.069/0.103
Synergistetes, Synergistia0.0000%0.0013%0.0412%*0.0480.230/0.230*0.032/0.0950.120/0.181
Acidobacteria, Solibacteres, Solibacterales, Solibacteraceae, Candidatus Solibacter0.0018%0.0047%0.0014%*0.036*0.041/0.0711.000/1.0000.047/0.071
Actinobacteria, Actinobacteria, Actinomycetales, Pseudonocardiaceae, (unknown genus)0.0000%0.0020%0.0000%*0.008*0.023/*0.0421.000/1.000*0.028/*0.042
Actinobacteria, Coriobacteriia, Coriobacteriales, Coriobacteriaceae, Collinsella0.0908%0.0624%0.2637%*0.0320.546/0.546*0.025/*0.039*0.026/*0.039
Firmicutes, Clostridia, Clostridiales, Lachnospiraceae, Lachnospira3.1468%1.5362%1.5014%*0.045*0.019/0.058*0.050/0.0740.648/0.648
Firmicutes, Clostridia, Clostridiales, Veillonellaceae, Megasphaera0.0000%0.1013%0.0441%*0.036*0.024/0.0720.334/0.3340.144/0.216
Firmicutes, Erysipelotrichi, Erysipelotrichales, Erysipelotrichaceae, (unknown genus)0.5217%0.2507%0.1486%*0.0300.092/0.138*0.017/0.0510.141/0.141
Firmicutes, Erysipelotrichi, Erysipelotrichales, Erysipelotrichaceae, Bulleidia0.0000%0.0000%0.0038%*0.0201.00/1.000.069/0.104*0.036/0.104
Proteobacteria, Gammaproteobacteria, Enterobacteriales, Enterobacteriaceae, (unknown genus)0.2465%0.4275%3.7804%*0.0160.786/0.786*0.010/*0.025*0.017/*0.025

N=NonDM, P=PreDM, D=T2DM

Indicates p <0.05

Based on PCA and PERMANOVA, a relationship between diagnosis group and micro biome composition were not significant (Supplemental Figure 1, Table 3). Based on Mantel test, we did not find a direct correlation between HbA1C level and dissimilarities in community composition (Table 3). PreDM and T2DM patients had slightly lower Shannon diversity indices, but this was non-significant (Figure 2).
Table 3

Results of PERMANOVA and Mantel testscalculated using Bray-Curtis, unweighted UniFrac, and eighted UniFrac. p value of > 0.05 represents diabetes diagnosis and A1C level and were not significant.

CorrectionPERMNOVAMANTEL
DiagnosisA1C value
p valuep valuerho
Bray-Curtis (BC)0.10.20.07
Unweighted UniFrac (UWUF)0.20.20.07
Weighted UniFrac (WUF)0.20.20.05
Figure 2

Results of Shannon diversity index. Vertical lines indicate range, squares represent mean values.

Discussion

This study evaluated the compositional changes in gut micro biota of normal, preDM and T2DM participants. The baseline characteristics of our study population show a significant difference between and among groups with regard to HbA1C, cholesterol, HDL, and LDL levels; however the remaining clinical parameters were not statistically different. Our results reveal dysbiosis in the gut microbiome of both preDM and T2DM patients in comparison to nonDM patients. We did not find an overall correlation between microbiome composition or diversity and HbA1C level. This indicates that there did not exist a particular pattern of bacterial abundance that associated with either HbA1C or diagnosis group. However, there were many differences found in the individual relative abundances of specific taxa between the three groups. This finding may indicate that there is not a specific gut pattern associated with glucose levels or the diabetic disease state; it may also mean that larger studies needed to see a consistent pattern. Looking at individual taxa, the preDM group in our study had a preponderance of the class Chloracidobacteria and an unknown genus from family Pseudonocardiaceae. Chloracidobacteria was belongs to phylum Acidobacteria, which is known to inhabit soil globally[, and has been found in small amounts on leaf salad vegetables[; however, it is not consistently reported in gut microbiome data. Pseudonocardiaceae belongs to phylum Actinobacteria, which has been increased in obesity[, but not consistently. The T2DM group had higher levels of genus Collinsella and an unknown genus belonging to the family Enterobacteriaceae. The increase in Collinsella in T2DM was a similar finding in[, and has been associated with symptomatic atherosclerosis in other studies[. This may be an indication that many of our T2DM subjects had co-morbid symptomatic atherosclerosis, which is expected in a diabetic population[. The family of Enterobacteriaceae contains many gram-negative, pathogenic genera such as: Escherichia, Klebsiella, Yersinia, Citrobacter, Proteus, Shigella, Salmonella, and Serratia. Lipo-polysaccharide (LPS), which is a cellular-membrane component of such gram-negative bacteria, is increased in both obese and T2DM subjects[; increased adherence of intestinal Escherichia coli (gram-negative) and a decrease in intestinal Bifidobacterium species are associated with increased serum LPS[. Qin, et al.[ did find T2DM group with increased levels of Escherichia coli, but not others from the family of Enterobacteriaceae. Our results were not analyzed to the species level. We did not observe differences in the abundances of phyla Bacteroidetes Firmicutes, classes Clostridia or Bacteroidia, nor in genera Streptococcus, Prevotella, or Megamonas as the previously reported[. Non-significance in some of our results may have been related to a relatively small sample size or related to a small amount of lost data after rarefaction to 14900 OTUs. There are many potential confounding factors when it comes to assessing intestinal microbiome. The known association between BMI, obesity and gut microbiome[ could have affected the results, though our three groups had mean BMIs, which were not statistically different (Table 1). Diet is a known factor in development of one's intestinal microbiome[, and could have affected our results as well. These participants reported whether they were vegetarian, lactose-free, or gluten-free, but other details of dietary habits were not explored. Diets high in carbohydrates have been associated with a preponderance of genus Prevotella and high fat/protein diets have been associated with higher levels of genus Bacteroides[. Medications such as Metformin have been associated with a change in gut microbiome; specifically one study found that there was an increase in Firmicutes and decrease in Bacteroidetes in patients taking Metformin[, the patients in this study were not questioned about Metformin specifically at the time of interview, but it can be assumed that some of the T2DM group was taking the medication, and possibly some of the preDM group as well. The effects of probiotics are currently being researched, and so far have reported to have significant effects on metabolism and intestinal mucosal integrity[. In this study, one patient from each of the diagnosis groups reported taking probiotics. We report dysbiosis associated with both preDM and T2DM, specifically at the class and genus levels suggesting that earlier treatment in preDM could possibly have an impact on the intestinal micro flora transitioning to T2DM.
  36 in total

1.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

2.  Dominant and diet-responsive groups of bacteria within the human colonic microbiota.

Authors:  Alan W Walker; Jennifer Ince; Sylvia H Duncan; Lucy M Webster; Grietje Holtrop; Xiaolei Ze; David Brown; Mark D Stares; Paul Scott; Aurore Bergerat; Petra Louis; Freda McIntosh; Alexandra M Johnstone; Gerald E Lobley; Julian Parkhill; Harry J Flint
Journal:  ISME J       Date:  2010-08-05       Impact factor: 10.302

3.  A metagenome-wide association study of gut microbiota in type 2 diabetes.

Authors:  Junjie Qin; Yingrui Li; Zhiming Cai; Shenghui Li; Jianfeng Zhu; Fan Zhang; Suisha Liang; Wenwei Zhang; Yuanlin Guan; Dongqian Shen; Yangqing Peng; Dongya Zhang; Zhuye Jie; Wenxian Wu; Youwen Qin; Wenbin Xue; Junhua Li; Lingchuan Han; Donghui Lu; Peixian Wu; Yali Dai; Xiaojuan Sun; Zesong Li; Aifa Tang; Shilong Zhong; Xiaoping Li; Weineng Chen; Ran Xu; Mingbang Wang; Qiang Feng; Meihua Gong; Jing Yu; Yanyan Zhang; Ming Zhang; Torben Hansen; Gaston Sanchez; Jeroen Raes; Gwen Falony; Shujiro Okuda; Mathieu Almeida; Emmanuelle LeChatelier; Pierre Renault; Nicolas Pons; Jean-Michel Batto; Zhaoxi Zhang; Hua Chen; Ruifu Yang; Weimou Zheng; Songgang Li; Huanming Yang; Jian Wang; S Dusko Ehrlich; Rasmus Nielsen; Oluf Pedersen; Karsten Kristiansen; Jun Wang
Journal:  Nature       Date:  2012-09-26       Impact factor: 49.962

Review 4.  Human microbiome in health and disease.

Authors:  Kathryn J Pflughoeft; James Versalovic
Journal:  Annu Rev Pathol       Date:  2011-09-09       Impact factor: 23.472

Review 5.  Compositional and functional features of the gastrointestinal microbiome and their effects on human health.

Authors:  Emily B Hollister; Chunxu Gao; James Versalovic
Journal:  Gastroenterology       Date:  2014-01-29       Impact factor: 22.682

Review 6.  Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications.

Authors:  Alejandra de Moreno de LeBlanc; Jean Guy LeBlanc
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

Review 7.  Microalbuminuria: a parameter that has changed diabetes care.

Authors:  Hans-Henrik Parving; Frederik Persson; Peter Rossing
Journal:  Diabetes Res Clin Pract       Date:  2014-10-24       Impact factor: 5.602

8.  Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults.

Authors:  Nadja Larsen; Finn K Vogensen; Frans W J van den Berg; Dennis Sandris Nielsen; Anne Sofie Andreasen; Bente K Pedersen; Waleed Abu Al-Soud; Søren J Sørensen; Lars H Hansen; Mogens Jakobsen
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

9.  Richness of human gut microbiome correlates with metabolic markers.

Authors:  Emmanuelle Le Chatelier; Trine Nielsen; Junjie Qin; Edi Prifti; Falk Hildebrand; Gwen Falony; Mathieu Almeida; Manimozhiyan Arumugam; Jean-Michel Batto; Sean Kennedy; Pierre Leonard; Junhua Li; Kristoffer Burgdorf; Niels Grarup; Torben Jørgensen; Ivan Brandslund; Henrik Bjørn Nielsen; Agnieszka S Juncker; Marcelo Bertalan; Florence Levenez; Nicolas Pons; Simon Rasmussen; Shinichi Sunagawa; Julien Tap; Sebastian Tims; Erwin G Zoetendal; Søren Brunak; Karine Clément; Joël Doré; Michiel Kleerebezem; Karsten Kristiansen; Pierre Renault; Thomas Sicheritz-Ponten; Willem M de Vos; Jean-Daniel Zucker; Jeroen Raes; Torben Hansen; Peer Bork; Jun Wang; S Dusko Ehrlich; Oluf Pedersen
Journal:  Nature       Date:  2013-08-29       Impact factor: 49.962

10.  Culture dependent and independent analysis of bacterial communities associated with commercial salad leaf vegetables.

Authors:  Colin R Jackson; Kevin C Randolph; Shelly L Osborn; Heather L Tyler
Journal:  BMC Microbiol       Date:  2013-12-01       Impact factor: 3.605

View more
  78 in total

1.  Low dietary fiber intake increases Collinsella abundance in the gut microbiota of overweight and obese pregnant women.

Authors:  Luisa F Gomez-Arango; Helen L Barrett; Shelley A Wilkinson; Leonie K Callaway; H David McIntyre; Mark Morrison; Marloes Dekker Nitert
Journal:  Gut Microbes       Date:  2018-03-13

2.  Early-Life Sugar Consumption Affects the Rat Microbiome Independently of Obesity.

Authors:  Emily E Noble; Ted M Hsu; Roshonda B Jones; Anthony A Fodor; Michael I Goran; Scott E Kanoski
Journal:  J Nutr       Date:  2016-11-30       Impact factor: 4.798

3.  Gut Microbiota Composition and Blood Pressure.

Authors:  Shan Sun; Anju Lulla; Michael Sioda; Kathryn Winglee; Michael C Wu; David R Jacobs; James M Shikany; Donald M Lloyd-Jones; Lenore J Launer; Anthony A Fodor; Katie A Meyer
Journal:  Hypertension       Date:  2019-05       Impact factor: 10.190

4.  Systematic Characterization and Analysis of the Taxonomic Drivers of Functional Shifts in the Human Microbiome.

Authors:  Ohad Manor; Elhanan Borenstein
Journal:  Cell Host Microbe       Date:  2017-01-19       Impact factor: 21.023

5.  Gut Microbiome Associates With Lifetime Cardiovascular Disease Risk Profile Among Bogalusa Heart Study Participants.

Authors:  Tanika N Kelly; Lydia A Bazzano; Nadim J Ajami; Hua He; Jinying Zhao; Joseph F Petrosino; Adolfo Correa; Jiang He
Journal:  Circ Res       Date:  2016-08-09       Impact factor: 17.367

6.  Bioremediation of a Common Product of Food Processing by a Human Gut Bacterium.

Authors:  Ashley R Wolf; Darryl A Wesener; Jiye Cheng; Alexandra N Houston-Ludlam; Zachary W Beller; Matthew C Hibberd; Richard J Giannone; Samantha L Peters; Robert L Hettich; Semen A Leyn; Dmitry A Rodionov; Andrei L Osterman; Jeffrey I Gordon
Journal:  Cell Host Microbe       Date:  2019-10-01       Impact factor: 21.023

7.  Abundance alteration of nondominant species in fecal-associated microbiome of patients with SAPHO syndrome.

Authors:  Jianhua Zhen; Yuxiu Sun; Pengfei Zhao; Chen Li; Hesong Wang; Yini Li; Lu Zhao; Li Wang; Guangrui Huang; Anlong Xu
Journal:  BMC Microbiol       Date:  2021-05-30       Impact factor: 3.605

8.  Helicobacter pylori infection-induced changes in the intestinal microbiota of 14-year-old or 15-year-old Japanese adolescents: a cross-sectional study.

Authors:  Toshihiko Kakiuchi; Yoshiki Tanaka; Hiroshi Ohno; Muneaki Matsuo; Kazuma Fujimoto
Journal:  BMJ Open       Date:  2021-07-02       Impact factor: 2.692

9.  Altered Actinobacteria and Firmicutes Phylum Associated Epitopes in Patients With Parkinson's Disease.

Authors:  Zhuo Li; Gang Lu; Zhe Li; Bin Wu; Enli Luo; Xinmin Qiu; Jianwen Guo; Zhangyong Xia; Chunye Zheng; Qiaozhen Su; Yan Zeng; Wai Yee Chan; Xianwei Su; Qiaodi Cai; Yanjuan Xu; Yingjun Chen; Mingbang Wang; Wai Sang Poon; Xiaodong Luo
Journal:  Front Immunol       Date:  2021-07-02       Impact factor: 7.561

10.  Effect of Fecal Microbiota Transplantation Combined With Mediterranean Diet on Insulin Sensitivity in Subjects With Metabolic Syndrome.

Authors:  Annefleur M Koopen; Eduardo L Almeida; Ilias Attaye; Julia J Witjes; Elena Rampanelli; Soumia Majait; Marleen Kemper; Johannes H M Levels; Alinda W M Schimmel; Hilde Herrema; Torsten P M Scheithauer; Werner Frei; Lars Dragsted; Bolette Hartmann; Jens J Holst; Paul W O'Toole; Albert K Groen; Max Nieuwdorp
Journal:  Front Microbiol       Date:  2021-06-10       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.